Promising Results From The Gastric Cancer Cohort Of Leap-005

Promising results from the gastric cancer cohort of LEAP-005

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

European Society for Medical Oncology (ESMO)

ASCO 2021: LEAP 005 (pembrolizumab and lenvatinib) Poster Walk with Dr Kurzrock

PALTOWN Development Foundation

LBA41 - LEAP-005: Phase II study of lenvatinib plus pembrolizumab

Pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancer

Pembrolizumab plus 5-FU and Cisplatin for First-Line Treatment in...

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric Cancer

Targeted Oncology

Lenvatinib and pembrolizumab in microsatellite stable CRC

Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric Cancer

Targeted Oncology

Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab

Targeted Oncology

Genomic landscape of late-stage gastric cancer treated with pembrolizumab

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

Perioperative pembrolizumab for stomach cancer treatment

Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies

ASCO GI: Adding Lenvatinib to Pembrolizumab in Patients With Advanced Gastric Cancer

Updated Results From an Observational Study of Nivolumab for Advanced Gastric Cancer

KEYNOTE-062: pembrolizumab vs. chemo in 1L advanced gastric cancer

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer